

## Chairman's Address Extraordinary General Meeting 28 April 2022

---

### **Reason for additional GM**

It is unusual for LCT to have more than one General Meeting per year, but sometimes circumstances dictate the need for these.

We had our Annual General Meeting on 11 November last year, and just 18 days later a second General Meeting. This was required to approve the issuing of additional shares and options, the bulk of which had been generated by 180 Markets in its support of LCT, which needed extra capital to pursue a third clinical trial with NTCELL.

This third General Meeting has been called to seek your approval for the issuing of additional options.

Additionally, we are seeking approval to refresh the capacity of the Company to raise further capital if required before the AGM scheduled for November.

For those seeking more details, I refer you to the Explanatory Memorandum issued at the time the General Meeting was called.

Once again, thank you for your attendance today and for your support of LCT. We greatly appreciate it.

### **NTCELL - Treatment of Parkinson's disease**

I would now like to provide an investor presentation for our shareholders.

Bernie Tuch

Executive Chairman